Product Description
Mechanisms of Action: NCCT Inhibitor, CA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Approved
Approved Countries: India | Pakistan | Taiwan
Approved Indications: None
Company: Broad Institute of MIT and Harvard
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Prion Diseases|Creutzfeldt-Jakob Syndrome|Gerstmann Syndrome|Insomnia, Fatal Familial|Gerstmann-Straussler-Scheinker Disease
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07444580 |
PRiSM | P1 |
Recruiting |
Gerstmann-Straussler-Scheinker Disease|Gerstmann Syndrome|Prion Diseases|Insomnia, Fatal Familial|Creutzfeldt-Jakob Syndrome |
2029-08-14 |
2026-04-23 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|